Presentation at the International Society of NeuroVirology 2022 of top-line data of academic collaborations further documenting the long-term expression of the Proinflammatory and Neuropathogenic W-ENV protein in cohorts of post-COVID Patients 

Geneva, Switzerland, October 17, 2022 – 7:30 am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Post-Acute Sequelae of COVID-19 (PASC, long-COVID or post-COVID), announced today that its Chief Scientific […]